Prelude Therapeutics (PRLD) Equity Average (2019 - 2026)

Prelude Therapeutics has disclosed Equity Average across 8 years of filings, most recently posting $64.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $64.4 million, down 45.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.4 million (down 45.1% YoY), and the FY2025 annual result was $100.0 million, down 45.71% from the prior year.
• Equity Average came in at $64.4 million for Q1 2026 at Prelude Therapeutics, up from $63.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $273.9 million in Q1 2022 to a low of $63.6 million in Q4 2025.
• The 5-year median for Equity Average is $196.5 million (2024), against an average of $175.8 million.
• Across the five-year window, Equity Average advanced 20.79% in 2024 and sank 60.33% in 2025, its largest moves.
• Prelude Therapeutics' Equity Average stood at $206.4 million in 2022, then grew by 15.14% to $237.7 million in 2023, then sank by 39.44% to $143.9 million in 2024, then slumped by 55.83% to $63.6 million in 2025, then increased by 1.3% to $64.4 million in 2026.
• The last three Equity Average figures came in at $64.4 million (Q1 2026), $63.6 million (Q4 2025), and $67.2 million (Q3 2025), per Business Quant data.